Professor Günter Höglinger, Lead Investigator of the Mascot trial, said: “Completing randomization of a global Phase 3 trial in MSA is a significant achievement for the field.” He added: “Advancing ...

Another phase III failure of Theravance Biopharma Inc.’s norepinephrine reuptake inhibitor ampreloxetine to treat symptomatic neurogenic orthostatic hypotension, this time in patients with the rare ...

Theravance Biopharma shares tumble after Phase 3 trial fails, company halts drug program and explores sale options ahead of earnings.

Theravance Biopharma said on Tuesday its board is reviewing strategic alternatives, including a ​possible sale, after scrapping development of an experimental drug for ‌a rare disorder, sending its ...

In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its ...

Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...

Dr. Laroy Borchert passed away on May 1, 2025, at the age of 68 in Tomball, TX. His courage and determination for life were present through the end of his struggle with Multiple Systems Atrophy, an ...

A new study by the University of Turku and Turku University Hospital, Finland, found that a significant proportion of Parkinson's disease diagnoses are later corrected. Up to one in six diagnoses ...

Add Yahoo as a preferred source to see more of our stories on Google. Multiple systems will bring the West beneficial rain and mountain snow. The first round moves in Wednesday into Thursday, but that ...

Sarma is presented as a system capable of delivering fewer but more accurate strikes while minimizing exposure of its crew.Dmitry/Aterrassi Russia has showcased its new multiple launch rocket system ...

MSA-P, parkinsonian-type multiple system atrophy; PD, Parkinson’s disease; HC, healthy controls; MDS-UPDRS, the Movement Disorder Society-sponsored revision of the Unified Parkinson’s disease rating ...